ProfoundBio secures $112m to advance ADC portfolio for cancer

ProfoundBio has secured $112m in a Series B financing round to advance its clinical-stage antibody-drug conjugate (ADC) pipeline for cancer treatment.

Related Keywords

Andrew Lam ,Enoch Kariuki ,Baiteng Zhao ,Eric Dobmeier ,T Rowe Price Associates , ,Ally Bridge Group ,Nextech Invest ,Price Associates ,Janus Henderson Investors ,Lilly Asia Ventures ,